ArriVent BioPharma (AVBP) Share-based Compensation (2023 - 2026)

ArriVent BioPharma has disclosed Share-based Compensation across 4 years of filings, most recently posting $5.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $5.5 million, up 141.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.7 million (up 224.21% YoY), and the FY2025 annual result was $12.5 million, up 290.27% from the prior year.
• Share-based Compensation came in at $5.5 million for Q1 2026 at ArriVent BioPharma, up from $3.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $216.0 million in Q3 2023 to a low of $166000.0 in Q1 2023.
• The 4-year median for Share-based Compensation is $2.3 million (2025), against an average of $33.1 million.
• Across the five-year window, Share-based Compensation slumped 99.6% in 2024 and surged 332.25% in 2025, its largest moves.
• ArriVent BioPharma's Share-based Compensation stood at $319000.0 in 2023, then soared by 198.12% to $951000.0 in 2024, then jumped by 238.8% to $3.2 million in 2025, then surged by 70.24% to $5.5 million in 2026.
• The last three Share-based Compensation figures came in at $5.5 million (Q1 2026), $3.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.